Latest News and Press Releases

Longeveron to report 3Q25 financial results and host investor/analyst call/webcast on Tuesday, November 4, 2025 after close of US financial markets.

Dr. Joshua Hare, CSO and Exec Chairman interviewed on NPR's BioTech Nation, discussing potential breakthrough stem cell therapy for HLHS.

Longeveron will participate in the 4th Annual ROTH Healthcare Opportunities Conference October 9, 2025 in New York City.

Longeveron announces closing of up to $17.5 million public offering. Proceeds to support potential BLA readiness activities, among other items.

Longeveron announces the pricing of a public offering of common stock and warrants.

Longeveron will report Q2 2025 financial results and provide a business update on Wednesday, August 13, 2025 after the U.S. financial markets close.

Longeveron CEO Wa’el Hashad will present at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference.

Longeveron selected as a Semi-Finalist Team and one of the Top 40 Teams receiving a $250,000 Milestone 1 Award in the XPRIZE Healthspan competition.

Longeveron (LGVN) will report Q1 2025 financial results and provide a business update on Thursday, May 8, 2025 after the U.S. financial markets close.

Longeveron positive Phase 2 clinical trial data in Alzheimer's disease published in peer reviewed journal Nature Medicine.